DAX+0,23 % EUR/USD+0,03 % Gold-0,15 % Öl (Brent)+0,32 %

DGAP-News: GPC Biotech AG english = - 500 Beiträge pro Seite

Beitrag schreiben

Begriffe und/oder Benutzer


Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. --------------------------------------------------------------------------------

GPC Biotech Announces Issuance of Two Patents for Anti-Fungal Drug Discovery Program Martinsried/Munich (Germany) and Waltham/Boston, MA (USA), September 10, 2001 -- GPC Biotech AG (Frankfurt Stock Exchange: GPC) today announced that the United States Patent and Trademark Office has issued two patents covering geranylgeranyl transferase type 1 (GGTase) as an anti-fungal drug target. The GGTase program is the Company`s most advanced anti-fungal drug discovery program. These patents provide GPC Biotech with a significant competitive advantage; they cover novel anti-fungal drug discovery assays and the commercial development of important new therapeutics for fungal diseases, based on a novel mechanism of action distinctly different from conventional therapies. US Patent 6,271,197 covers drug screening assays for identifying inhibitors of fungal GGTase activity. The patent also includes "reach-through" claims covering methods for treating fungal infections using any drug identified through assays claimed in the patent. The patent is jointly owned by GPC Biotech and The Johns Hopkins University, which has granted GPC Biotech an exclusive worldwide license to the subject matter contained in the patent. US Patent 6,277,564, which is owned by GPC Biotech, covers the nucleic acid sequence of an essential subunit of Candida albicans GGTase and an expression construct of the nucleic acid. These two newly issued patents further strengthen GPC Biotech`s broad intellectual property position in the anti-fungal area, which includes four additional issued patents and 30 pending patent applications covering the composition of matter for anti-fungal drug targets and small molecule compounds identified in GPC Biotech`s patented anti-fungal drug screening assays. Bernd R. Seizinger, M.D., Ph.D., President and CEO of GPC Biotech commented, "The issuance of these two patents significantly strengthens our anti-fungal drug discovery portfolio. However, since GPC Biotech is increasingly focusing on the development of its internal oncology programs, we intend to eventually out- license or partner our exciting anti-fungal GGTase program." GPC Biotech`s lead anti-fungal drug discovery program is a novel approach directed towards GGTase type 1 which regulates an important signalling pathway required for fungal cell wall integrity. GGTase as a new anti-fungal drug target offers the opportunity to discover and develop small molecule inhibitors that kill the fungal pathogen. Through targeting this new mechanism of action GPC Biotech seeks to overcome the limitations of the currently available anti-fungal drugs, that are either susceptible to resistance due to their lack of a killing effect, or are fraught with serious side effects limiting their use to treatment of only serious fungal infections. GPC Biotech has genetically validated the GGTase target and identified potent small molecule inhibitors showing high selectivity for the fungal enzyme versus the human counterpart, thereby minimizing the probability of side effects. Fungal infections, including Candida albicans, are among the most common hospital infections, particularly affecting immune-suppressed patients. For example, fungal infections can potentially represent life-threatening situations for patients undergoing anti-cancer therapies or transplantations. Moreover, fungi have become increasingly resistant to traditional drug treatments, thereby urgently requiring novel targets for anti-fungal therapies. GPC Biotech AG is a genomics- and proteomics-driven drug discovery company focused on applying a number of proprietary genomic, proteomic and drug discovery technologies to accelerate the identification and validation of novel drug targets for development of mechanism-based drugs in oncology, infectious diseases and immunology. GPC Biotech has leading cell cycle expertise and a broad intellectual property position with 62 patents issued, that are wholly owned, co-owned or exclusively/co-exclusively licensed, and over 180 patents pending. Drug discovery alliance partners include: Aventis Pharma (PAVE.PSE), Bayer AG (BAY.FSE), DuPont Pharmaceuticals (DD-B.NYS), Boehringer Ingelheim International GmbH, the Altana AG (ALT.FSE) subsidiary Byk Gulden, Cell Genesys, Inc. (CEGE.NAS), MorphoSys AG (MOR.FSE) and Karo Bio USA (KARO.SSE). GPC Biotech AG is headquartered in Martinsried/Munich (Germany) with two wholly owned US subsidiaries in Waltham/Boston, MA and in Princeton, NJ. For further information, please visit the corporate website at: http://www.gpc-biotech.com. The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks which cannot be foreseen and which are beyond the control of GPC Biotech AG. GPC Biotech AG is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of GPC Biotech AG or the market in the shares of GPC Biotech AG. For further information please contact: GPC Biotech AG Petra Bassen Head of Investor Relations & Corporate Communications Phone: +49 (0)89 8565-2691 Fax: +49 (0)89 8565-2610 petra.bassen@gpc-biotech.com

Eva Grabner Investor Relations & Corporate Communications Specialist Phone: +49 (0)89 8565-2693 eva.grabner@gpc-biotech.com

end of message, (c)DGAP 10.09.2001 -------------------------------------------------------------------------------- WKN: 585150; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart

100914 Sep 01

Autor: DGAP import (),09:18 10.09.2001

Beitrag zu dieser Diskussion schreiben

Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.